|
Activity Number:
|
223
|
|
Type:
|
Invited
|
|
Date/Time:
|
Tuesday, July 31, 2007 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307891 |
|
Title:
|
Gene Signatures for Hepatotoxicants
|
|
Author(s):
|
Nandini Raghavan *+ and Dhammika Amaratunga and Alex Nie and Michael McMillian
|
|
Companies:
|
Johnson & Johnson PRD and Johnson & Johnson PRD and Johnson & Johnson PRD and Johnson & Johnson PRD
|
|
Address:
|
G-031, 1000 Rt. 202-S., Raritan, NJ, ,
|
|
Keywords:
|
genomics ; microarray ; gene signatures ; classification ; toxicity ; pharmaceutical
|
|
Abstract:
|
Toxicogenomics is an evolving area that attempts to exploit new high-throughput "omics" technologies to develop faster, better and earlier safety screens for drugs. Improving the screening process for new compounds to predict toxicity issues early in discovery will enable pharmaceutical companies to reduce the costs of developing new drugs significantly. In this talk we discuss some of the issues arising in the design and analysis of toxicogenomic experiments, as well as methods for classifying compounds into various hepatotoxicity classes. We also discuss the incorporation of genomic databases to construct biologically relevant gene signatures for predicting toxicity in new compounds, and cross-platform comparisons of gene signatures. We will also present the results of a large-scale study at Johnson and Johnson.
|
